All In Biotech

Drug Trial Radar · NCT03925857

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jan 27, 2019

Primary completion

Dec 10, 2019

Study completion Jan 12, 2020

Sponsor

Lead sponsor
Enlivex Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Apr 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial evaluates the safety and efficacy of one and two doses of the study drug, Allocetra-OTS, in patients who have been diagnosed with sepsis.

Conditions

  • Organ Dysfunction Syndrome Sepsis

Interventions

  • Allocetra-OTSBiological

    Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety by determining the number of participants with any Adverse Events (AE),Serious Adverse Events (SAE) and fatal SAETime frame: 28 days follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.